Mesentech
Karen Long has extensive work experience in regulatory affairs and drug development. Karen is currently employed as the Sr. Director of Development at Mesentech, starting in November 2022. Prior to this, Karen held director-level positions at InMed Pharmaceuticals, where they served as the Director of Drug Development starting in July 2017 and then promoted to Sr. Director in May 2019. Karen also worked as a Drug & Device Regulatory Affairs Lead at Novateur Ventures Inc. from November 2015 to July 2017. Before that, Karen held a senior regulatory affairs specialist/compliance specialist role at STEMCELL Technologies from September 2014 to June 2017. Karen also worked as a Director of Regulatory Affairs at Neovasc Inc. from April 2013 to July 2014 and as a Regulatory Affairs Consultant from July 2012 to March 2013. Additionally, Karen has experience as a Regulatory Affairs Manager at QLT Inc. from October 2011 to July 2012 and at Angiotech from March 2006 to October 2011. Karen began their career as the Regulatory Affairs Chair at Student Biotech Network from 2005 to 2006 and worked as a Manager of CMC Regulatory Affairs at Tekmira-formerly Inex Pharmaceuticals from 2001 to 2003.
Karen Long has a solid educational background in the field of pharmaceutical science and chemistry. Karen earned their Bachelor of Science degree with Honors in Chemistry from The University of British Columbia, where they attended from 1985 to 1989. Following that, Karen pursued a Master's degree in Pharmaceutical Science at the same university from 2003 to 2006.
In addition to their academic achievements, Karen Long has obtained several certifications related to regulatory affairs. Karen completed the Regulatory Affairs Certification Program, earning certifications in RAC-Canada in 2007, RAC-EU in 2006, RAC-Global in 2010, and RAC-US in 1999. Furthermore, they became an ISO 13485 Lead Auditor through BSI in 2012. Karen is also a member of the Regulatory Affairs Professional Society (RAPS), having joined in 1999.
There is no available information on Karen's education prior to their time at The University of British Columbia.
This person is not in any teams
Mesentech
Mesentech is a company focused on treating diseases and medical conditions that relate to bone. They are generating a series of products, from different, but complementary approaches that will effectively address currently difficult to treat conditions.Bone can be one of the most difficult organs to access and treat with medicines. It’s hardsurface and low porosity presents challenges in adequately getting drugs to either the bone surface or to its interior. Treatment often requires administering high doses of a drug over extended periods. Not only is achievement of efficacy compromised, but also side- effects may be more prevalent and can limit treatment effectiveness.Mesentech’s lead technology is a proprietary bone targeting system that can effectively deliver small-molecule and biological drugs to the surface or to the interior of bone. Pre-clinical in-vivo models have confirmed the utility of this technology.